The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1331
February 8, 2010
View Complete Issue         Table of Contents 2019 
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
February 8, 2010 (Issue: 1331)
Asenapine (Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
Article code: 1331a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.